Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
AQUILA trial criteria may have classified approximately 3 times more patients with smoldering myeloma as having high risk compared with the 2/20/20 model and captured a group with substantially lower progression risk.”
Title: Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention
Authors: Cecilie V. Maeng, Sæmundur Rögnvaldsson, Christian Brieghel, Morten N. Andersen, Ida B. Kristensen, Agoston Szabo, Kirsten Grønbæk, Carsten U. Niemann, Sigurdur Y. Kristinsson, Sigrún Thorsteinsdóttir
You can read the Full Article in JAMA Oncology.
You can find other articles featuring Robert Orlowski on OncoDaily.
